Group 1 - The core viewpoint of the news is that Yidu Tech (02158) has been actively repurchasing its shares, demonstrating confidence in its intrinsic value and a clear intention to maintain its market capitalization [1] - On February 6, the company repurchased approximately 1.6 million shares at around HKD 5.63 per share, with a total expenditure exceeding HKD 9 million, marking the tenth consecutive trading day of intensive buybacks [1] - Cumulatively, the total amount spent on share repurchases has reached approximately HKD 53 million, indicating a consistent and robust buyback strategy [1] Group 2 - Citigroup has maintained a "Buy" rating for Yidu Tech and raised its target price to HKD 11, anticipating a potential upside of over 96% for the stock price [1] - The company is recognized for its unique advantage in data quality and authority, stemming from its collaboration with top hospitals, which is crucial for the accuracy of medical AI models [1] - The business segment targeting government and hospitals shows more predictable profitability compared to consumer applications, benefiting directly from increased AI budgets in hospitals and national project tenders [2] Group 3 - Citigroup has revised its financial forecasts for Yidu Tech, projecting a 17% and 30% year-on-year growth in revenue from its big data platform for the fiscal years 2026 and 2027, respectively [2] - The company is expected to reach breakeven in the fiscal year 2026, reflecting a solid business model and clear growth trajectory [2]
医渡科技连续10日回购累计约5300万港元 花旗上调目标价至11港元